SOST and metabolic dysfunction-associated steatotic liver disease: In both the NAFLD patients and controls, circulating sclerostin levels were not different between male and female (Supplementary Figure 1), and no significant correlation between sclerostin and gender was found (r=-0.115, p=0.297 in NAFLD; r=0.102, p=0.189 in controls).